Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY – Get Free Report) shares saw unusually-strong trading volume on Friday . Approximately 38,839 shares traded hands during trading, an increase of 2% from the previous session’s volume of 38,163 shares.The stock last traded at $31.92 and had previously closed at $32.40.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on OTSKY shares. The Goldman Sachs Group lowered shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. Zacks Research raised shares of Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Otsuka currently has a consensus rating of “Hold”.
Get Our Latest Stock Analysis on Otsuka
Otsuka Price Performance
Otsuka (OTCMKTS:OTSKY – Get Free Report) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The firm had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Equities research analysts expect that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current fiscal year.
About Otsuka
Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.
Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.
Read More
- Five stocks we like better than Otsuka
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.
